A new personalized mRNA melanoma vaccine developed by Moderna and Merck is showing promising results, cutting the risk of cancer recurrence nearly in half for high-risk patients.

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

Covid vaccines may come with a tantalizing benefit that has nothing to do with the virus they’re designed to protect against: boosting the immune system to better fight tumors during cancer treatment.

Add Yahoo as a preferred source to see more of our stories on Google. A nurse draws up doses of the Moderna COVID-19 for a vaccination clinic in St. Helena in 2021. Moderna is offering a new, low-dose ...

MRNA remains under pressure in 2025, despite recent next-gen COVID vaccine approval and upcoming cancer vaccine trial readouts. MRNA has a fully enrolled, 1089-patient study of mRNA-4157 in melanoma ...

An mRNA influenza vaccine was approximately 35% more effective than an inactivated quadrivalent flu vaccine against two different strains, based on new data from a phase 3 randomized trial. Although ...

Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported. The results, published Nov. 19 in The New England Journal of Medicine, suggest that ...

Researchers are edging closer to something long imagined but never quite within reach: a single vaccine platform that could be adapted to fight many kinds of cancer. Early experiments in animals and ...

At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to cancer and rare disease mRNA programs.

Cancer researchers have chased the idea of a universal cancer vaccine for decades. The promise sounds bold and almost impossible at first. One platform would help the immune system recognize many ...